BioNTech is preparing for its next phase.

The biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors. It owns and manages an AI developer, InstaDeep. 10 stocks we like better than BioNTech Se › ...

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

BioNTech and Chinese peer Duality Biologics announced before market open that a phase 3 clinical trial of their cancer drug trastuzumab pamirtecan met its primary endpoint of progression-free survival ...

BioNTech SE (BNTX), the Mainz, Germany-headquartered pharmaceutical company that co-developed the messenger RNA-based COVID vaccine, Comirnaty, alongside Pfizer (PFE), during the pandemic, announced ...

BioNTech (NasdaqGS:BNTX) named Dr. Guido Oelkers as incoming CEO, marking a major leadership transition at the company. The ...

Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine maker ...

BioNTech SE's $11.1bn BMS deal for BNT-327 highlights promise in PD-L1/VEGF oncology, but clinical validation is still needed. Despite strong COVID vaccine cash flow, BioNTech's share price stagnates ...

Now, it’s worth noting Stock Advisor’s total average return is 908 % — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Cathie Wood's biotech ETF has largely moved on from the vaccine maker.

Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer. Rather ...

Last quarter's reported loss isn't the problem. Although it was slightly bigger than expected, the analyst community knew the company would likely remain in the red due to a revenue headwind for the ...